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Elephant in the Room
Look at the Red Blood CellsWe read with great interest the paper by Silvain et al. (1) on the
impact of red blood cell transfusion on platelet aggregation and in-
ﬂammatory response in anemic coronary and noncoronary patients.
The authors should be commended on a well-planned and well-
conducted study regarding a somewhat neglected aspect of
our therapeutic practice. We would like to point out, however, that
much of the discussion surrounding this and other related reports on
red blood cell transfusions in patients with heart disease is focused on
how they affect platelet function and other aspects of the coagulation
system. However, we should not miss the giant elephant in the
roomdthe red blood cells themselves. By transfusing blood to pa-
tients, we administer some billions of red blood cells that have been
submitted to a tedious procedure of collection, processing, and
storage in packed red blood cell units. This process is known to
produce alterations that lead to hemolysis and the formation
of erythrocyte microparticles (2). Free hemoglobin is an extremely
oxidative and vasospastic agent, and red blood cell microparticles
have been shown to be associated with endothelial dysfunction and
prothrombotic phenomena (3,4). As a result, red blood cells them-
selves (with no need to affect platelets in any signiﬁcant way) may
be a major determinant of transfusion adverse effects on cardiovas-
cular outcomes. This may also explain, at least in part, why the
authors found no connection between the storage duration of blood
units with platelet aggregation parameters: storage affects red blood
cells, which in turn may lead to the described unwanted cardiovas-
cular effects, in a way virtually unrelated to platelet function.*Georgios Giannopoulos, MD
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65:1164–73.ReplyDo Not Miss the
Elephant in the Room
Look at the Red Blood CellsWe thank Drs. Giannopoulos and Deftereos for their excellent
comments on the potential role of red blood cells (RBCs) as an
explanation for the excess of risk due to RBC transfusion.
We share their view on this point as data show an association
between cell-free, hemoglobin-based blood substitutes and the
risk of myocardial infarction and death (1) that is very similar to
the one found in registries between RBC transfusion and poor
outcomes in coronary patients. Unfortunately, we lack evidence on
the impact of cell-free hemoglobin through endothelial dysfunc-
tion and prothrombotic effects in patients receiving a RBC
transfusion.
We believe that activation of the P2Y purinergic receptors
is one of the relevant mechanisms, as demonstrated in our pre-
vious in vitro study (2). Indeed, platelet reactivity was increased
using different assays including light transmission aggregometry
to adenosine diphosphate (ADP), collagen, and vasodilator-
stimulated phosphoprotein phosphorylation platelet reactivity
index (VASP-PRI), highly speciﬁc tests suggesting a partial
activation of the P2Y12 receptors. We concluded that the
release of ADP from RBCs might be readily liberated in the
context of blood storage, thus representing a potential stimulus
for platelet activation and aggregation. The results of the
TRANSFUSION-2 study (3) support this hypothesis as the
impact on platelet reactivity was found only with tests exploring
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2589the P2Y12 receptor pathway and that a correlation between
VASP-PRI increase and the duration of RBC storage was found
only with this test.
Moreover, it cannot be excluded that there is an even bigger
elephant in the room, as even with the best adjusting factors, the
real effect of RBC transfusion on the outcomes of coronary patients
might be confounded by cessation of life-saving medications. This
is likely the case with antithrombotic agents in patients bearing
both a high risk of bleeding and experiencing a highly thrombotic
situation such as acute coronary syndromes.
At this stage, as suggested in the accompanying editorial of Rao
et al. (4), only a well-sized randomized trial with speciﬁc data
collection (e.g., withdrawal of medication, storage of red blood
cells) could answer both important questions of the real clinical
impact of red blood cell transfusion in coronary patients and the
possible mechanistic explanations for it.*Johanne Silvain, MD, PhD
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Emission Tomography
as a Prognostic Indicator
of Cardiac SarcoidosisCardiac positron emission tomography (PET) is now one of
the most important diagnostic tools for the assessment of
cardiac sarcoidosis (CS). The diagnostic accuracy of PET has
been reported to exhibit 100% sensitivity and 80% to 90%
speciﬁcity (1,2). In a recent issue of the Journal, Blankstein et al.
(3) demonstrated that the presence of focal perfusion defect and
F-18 ﬂuorodeoxyglucose (FDG) uptake on cardiac PET identi-
ﬁed patients at higher risk of death or ventricular tachycardia
(VT). The focal FDG uptake in the right ventricle was also a
very speciﬁc ﬁnding of CS. Although the results are inter-
esting, there are several problems in the paper that should be
acknowledged.
The ﬁrst issue is the lack of an evaluation of treatment before
and after the diagnosis of CS. With effective anti-inﬂammatory
treatment, the FDG uptake on PET will be diminished, but if
the extent of inﬂammation is advanced, only a partial effect can be
obtained. The relationship between PET and treatment should
thus be clariﬁed.
The second issue relates to the Japanese Ministry of Health and
Welfare guidelines. Reference 6 in the original article by Kida et al.
2013 is not appropriate as a reference for these guidelines; it is
simply a small clinical study of cardiac magnetic resonance imaging.
The quoted guideline is an older version of the guideline in
reference (4) by Hiraga et al. 1993, which was revised in 2006, and
the clinical diagnosis group was newly set as a diagnostic criterion
(5). It would therefore be interesting to compare both clinical and
histological diagnoses by using the 2006 Japanese guidelines.
Third, regarding the baseline characteristics of the patients
(Table 1 [3]), 90% of the patients with adverse events had
an implantable cardioverter-deﬁbrillator (ICD) at baseline or on
follow-up. Of 31 outcomes, there were 28 VT events. The reasons
for the ICD implantations at baseline should be described because
VT events tend to occur in patients with ICDs.
Fourth, the fasting time of 3 h is apparently insufﬁcient to
inhibit physiological uptake in nonaffected myocardium. We have
recently reported that a long fasting time (>18 h) is necessary for
the precise evaluation of cardiac PET (6).
Endomyocardial biopsy (EMBx) is usually performed because
the diagnosis of CS is based principally on histology. However,
the diagnostic rate achieved with EMBx has been reported to
range from 20% to 30% (7). The paper by Blankstein et al. (3)
reports very interesting ﬁndings about EMBx from the right
ventricle. The overall diagnostic rate was 27%, but among the 20
patients with abnormal perfusion and FDG uptake, 45% had
positive ﬁndings. These results indicate that a positive PET
ﬁnding is useful not only for predicting outcomes but also for
determining the indications for performing an EMBx. Further
study is needed to resolve the issue of whether a positive PET
ﬁnding of myocardium can improve the diagnostic rate of
EMBx.
